Kahn, S. E., Haffner, S. M., Viberti, G., Herman, W. H., Lachin, J. M., Kravitz, B. G., . . . Zinman, B. (2010). Rosiglitazone Decreases C-Reactive Protein to a Greater Extent Relative to Glyburide and Metformin Over 4 Years Despite Greater Weight Gain: Observations from A Diabetes Outcome Progression Trial (ADOPT). American Diabetes Association.
Čikaški stil citiranjaKahn, Steven E., et al. Rosiglitazone Decreases C-Reactive Protein to a Greater Extent Relative to Glyburide and Metformin Over 4 Years Despite Greater Weight Gain: Observations From A Diabetes Outcome Progression Trial (ADOPT). American Diabetes Association, 2010.
MLA način citiranjaKahn, Steven E., et al. Rosiglitazone Decreases C-Reactive Protein to a Greater Extent Relative to Glyburide and Metformin Over 4 Years Despite Greater Weight Gain: Observations From A Diabetes Outcome Progression Trial (ADOPT). American Diabetes Association, 2010.